Efficacy of Upadacitinib in Managing Coexisting Psoriasis and Lichen Planus: A Case Study
-
By
-
Xingmo Li
-
Jinxu Qi
-
Liping Shi
-
Lijuan Liu
-
Xiaoyu Xie
-
Guoqiang Zhang
-
Qing Zhu
-
April 20, 2026
-
Clinical Scorecard: Efficacy of Upadacitinib in Managing Coexisting Psoriasis and Lichen Planus: A Case Study
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Involvement of T-cell mediated immune response and dysregulation of immune system in psoriasis and lichen planus. |
| Target Population | |
| Care Setting | |
Key Highlights
- First reported case of psoriasis combined with lichen planus treated with upadacitinib, demonstrating significant clinical improvement.
- Initial treatments included acitretin and topical mometasone, which were self-discontinued by the patient due to safety concerns.
- Upadacitinib showed marked improvement within 3 months, indicating its potential efficacy in this rare combination.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
- Monitor for efficacy and safety of upadacitinib, especially regarding potential adverse effects such as infections, liver function, and blood counts.
Risks
Patient & Prescribing Data
Upadacitinib was effective after previous treatments were discontinued due to safety concerns, highlighting the need for careful treatment selection.
Clinical Best Practices
- Evaluate comorbidities in patients with psoriasis, including mental health and other autoimmune conditions.
- Consider patient history and safety concerns when prescribing treatments, particularly in patients with complex comorbidities.
References
